The results of all these investigations, taken together, validate that invariably better survival in glioma patients with respect to IDH1 mutant tumors can mainly be attributed to less aggressive oncogenic mode and is less likely due to outcome of treatment by chemotherapy. The gene discussed is IDH1; the disease is glioma.